Latest News and Press Releases

Alzamend to Present at 2025 Military Health System Research Symposium; Differences in Lithium Brain-to-Plasma Exposure Between AL001 and Lithium Carbonate

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs; Net Cash Financings Year-Ended April 30, 2025, $10.4 Million

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule; Capital Raised to Support Five Clinical Trials

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Mass. General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Mass. General Hospital; Topline Data by Year-End

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for Its Phase II Clinical Trial of AL001 Study to Take Place at Mass. General Hospital

ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of...

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital